Research Analysts Issue Forecasts for NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Brookline Capital Acquisition issued their Q1 2026 earnings per share estimates for shares of Intellia Therapeutics in a research report issued on Thursday, February 26th. Brookline Capital Acquisition analyst L. Cann expects that the company will post earnings per share of ($0.85) for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Acquisition also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.53) EPS, FY2028 earnings at $17.06 EPS and FY2029 earnings at $46.29 EPS.

Other research analysts have also issued reports about the stock. KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a report on Wednesday, January 28th. Robert W. Baird set a $7.00 target price on shares of Intellia Therapeutics in a report on Tuesday, January 27th. Citizens Jmp lowered their target price on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, January 22nd. Finally, Wedbush reduced their price objective on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.48.

Intellia Therapeutics Price Performance

NTLA stock opened at $14.28 on Friday. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -3.34 and a beta of 2.10. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The firm has a fifty day moving average price of $11.80 and a two-hundred day moving average price of $13.00.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.27) EPS.

Insider Transactions at Intellia Therapeutics

In related news, EVP James Basta sold 10,397 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. This represents a 9.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the sale, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics during the 3rd quarter valued at about $30,000. Blue Bell Private Wealth Management LLC bought a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $30,000. Advisory Services Network LLC bought a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $33,000. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics during the second quarter valued at approximately $26,000. Finally, Comerica Bank raised its holdings in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 beat — Intellia reported a narrower-than-expected loss (EPS -$0.83 vs. -$0.99 est.) and revenue of $23.02M (well above estimates), with revenue up ~78% year-over-year; that earnings surprise is a key catalyst for the stock. Intellia Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: Strong cash runway — Intellia ended 2025 with approximately $605M in cash, providing runway to advance multiple programs and de-risk near-term milestones. This cash position supports R&D and commercial preparation. Q4 & Full-Year 2025 Financial Results
• Positive Sentiment: Clear near-term commercial path for lonvo‑z — Management guided to HAELO Phase 3 data by mid‑2026, a potential BLA submission in 2H‑2026 and U.S. launch in 1H‑2027, which could materially re-rate the company if successful. Business Updates & Timelines
• Neutral Sentiment: Management tone and strategic updates from the earnings call emphasized clinical progress, commercial readiness and long-term CRISPR strategy—helpful context but dependent on upcoming data and approvals. Earnings Call Transcript
• Negative Sentiment: Regulatory risk: an FDA clinical hold remains for the MAGNITUDE Phase 3 trial of nex‑z in ATTR‑CM; management is engaging FDA but resolution timing is uncertain and could delay or impair that program’s value. Earnings Call Highlights & Regulatory Update
• Negative Sentiment: Profitability risk: despite the quarter-over-quarter improvement, Intellia remains unprofitable with large negative margins and analyst forecasts calling for steep net losses ahead, leaving the stock sensitive to R&D setbacks or slower-than-expected commercial progress. Zacks Q4 Coverage

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.